The delivery method will provide benefits of cannabinoid-based healthcare research to medical professionals and patients looking for innovative products.
The product can be formulated in different dosage levels to be used for the majority of illnesses in which cannabis was found to be effective.
Cannabinoid-based products will have to meet medical grade criteria and dosing will be part of the eventual overall acceptance, the company said.
Medical Marijuana president Michael Llamas said the acquisition will not only expand company’s portfolio of patented products, but also solidifies its presence in the cannabinoid medicinal arena.